23andMe Holding Co. Logo

23andMe Holding Co.

ME

(1.2)
Stock Price

3,00 USD

-199.39% ROA

-189.28% ROE

-0.23x PER

Market Cap.

148.665.759,00 USD

51.68% DER

0% Yield

-317.03% NPM

23andMe Holding Co. Stock Analysis

23andMe Holding Co. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

23andMe Holding Co. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.58x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (12%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

4 ROE

The stock's ROE indicates a negative return (-44.16%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-71.05%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-1), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

23andMe Holding Co. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

23andMe Holding Co. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

23andMe Holding Co. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

23andMe Holding Co. Revenue
Year Revenue Growth
2018 440.900.000
2019 305.463.000 -44.34%
2020 243.920.000 -25.23%
2021 271.893.000 10.29%
2022 299.489.000 9.21%
2023 199.996.000 -49.75%
2023 219.638.000 8.94%
2024 161.656.000 -35.87%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

23andMe Holding Co. Research and Development Expenses
Year Research and Development Expenses Growth
2018 140.532.000
2019 181.276.000 22.48%
2020 159.856.000 -13.4%
2021 189.377.000 15.59%
2022 222.596.000 14.92%
2023 218.352.000 -1.94%
2023 205.361.000 -6.33%
2024 171.020.000 -20.08%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

23andMe Holding Co. General and Administrative Expenses
Year General and Administrative Expenses Growth
2018 50.293.000
2019 59.392.000 15.32%
2020 99.149.000 40.1%
2021 97.383.000 -1.81%
2022 115.984.000 16.04%
2023 119.784.000 3.17%
2023 148.329.000 19.24%
2024 151.724.000 2.24%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

23andMe Holding Co. EBITDA
Year EBITDA Growth
2018 -178.882.000
2019 -145.774.000 -22.71%
2020 -164.950.000 11.63%
2021 -260.994.000 36.8%
2022 -287.513.000 9.22%
2023 -262.844.000 -9.39%
2023 -291.875.000 9.95%
2024 -264.676.000 -10.28%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

23andMe Holding Co. Gross Profit
Year Gross Profit Growth
2018 182.989.000
2019 137.432.000 -33.15%
2020 117.006.000 -17.46%
2021 132.945.000 11.99%
2022 134.496.000 1.15%
2023 86.916.000 -54.74%
2023 99.377.000 12.54%
2024 58.912.000 -68.69%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

23andMe Holding Co. Net Profit
Year Net Profit Growth
2018 -183.533.000
2019 -289.311.000 36.56%
2020 -183.364.000 -57.78%
2021 -217.490.000 15.69%
2022 -311.656.000 30.21%
2023 -301.080.000 -3.51%
2023 -666.704.000 54.84%
2024 -277.600.000 -140.17%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

23andMe Holding Co. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2018 0
2019 -1 0%
2020 0 0%
2021 -1 0%
2022 -1 0%
2023 -1 0%
2023 -1 100%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

23andMe Holding Co. Free Cashflow
Year Free Cashflow Growth
2018 -125.957.000
2019 -259.354.000 51.43%
2020 -81.626.000 -217.73%
2021 -180.801.000 54.85%
2022 -176.695.000 -2.32%
2023 -165.185.000 -6.97%
2023 -59.892.000 -175.8%
2024 -44.574.000 -34.37%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

23andMe Holding Co. Operating Cashflow
Year Operating Cashflow Growth
2018 -98.117.000
2019 -185.766.000 47.18%
2020 -74.252.000 -150.18%
2021 -166.828.000 55.49%
2022 -165.390.000 -0.87%
2023 -155.529.000 -6.34%
2023 -57.119.000 -172.29%
2024 -43.270.000 -32.01%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

23andMe Holding Co. Capital Expenditure
Year Capital Expenditure Growth
2018 27.840.000
2019 73.588.000 62.17%
2020 7.374.000 -897.94%
2021 13.973.000 47.23%
2022 11.305.000 -23.6%
2023 9.656.000 -17.08%
2023 2.773.000 -248.21%
2024 1.304.000 -112.65%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

23andMe Holding Co. Equity
Year Equity Growth
2018 313.801.000
2019 134.199.999 -133.83%
2020 -595.619.000 122.53%
2021 915.656.000 165.05%
2022 713.939.000 -28.25%
2023 188.520.000 -278.71%
2023 625.251.000 69.85%
2024 143.504.000 -335.7%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

23andMe Holding Co. Assets
Year Assets Growth
2018 696.683.000
2019 404.630.000 -72.18%
2020 452.098.000 10.5%
2021 1.152.068.000 60.76%
2022 942.598.000 -22.22%
2023 395.167.000 -138.53%
2023 801.230.000 50.68%
2024 368.047.000 -117.7%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

23andMe Holding Co. Liabilities
Year Liabilities Growth
2018 382.882.000
2019 270.430.000 -41.58%
2020 1.047.717.000 74.19%
2021 236.412.000 -343.17%
2022 228.659.000 -3.39%
2023 206.647.000 -10.65%
2023 175.979.000 -17.43%
2024 224.543.000 21.63%

23andMe Holding Co. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.4
Net Income per Share
-1.27
Price to Earning Ratio
-0.23x
Price To Sales Ratio
0.75x
POCF Ratio
-1.13
PFCF Ratio
-1.08
Price to Book Ratio
1.02
EV to Sales
0.26
EV Over EBITDA
-0.88
EV to Operating CashFlow
-0.4
EV to FreeCashFlow
-0.37
Earnings Yield
-4.33
FreeCashFlow Yield
-0.93
Market Cap
0,15 Bil.
Enterprise Value
0,05 Bil.
Graham Number
2.88
Graham NetNet
-0.05

Income Statement Metrics

Net Income per Share
-1.27
Income Quality
0.2
ROE
-1.89
Return On Assets
-1.72
Return On Capital Employed
-2.28
Net Income per EBT
1
EBT Per Ebit
1.29
Ebit per Revenue
-2.47
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0.66
Research & Developement to Revenue
0.93
Stock Based Compensation to Revenue
0.46
Gross Profit Margin
0.42
Operating Profit Margin
-2.47
Pretax Profit Margin
-3.17
Net Profit Margin
-3.17

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.26
Free CashFlow per Share
-0.28
Capex to Operating CashFlow
-0.06
Capex to Revenue
0.04
Capex to Depreciation
0.3
Return on Invested Capital
-2.26
Return on Tangible Assets
-1.99
Days Sales Outstanding
50.88
Days Payables Outstanding
35.29
Days of Inventory on Hand
46.5
Receivables Turnover
7.17
Payables Turnover
10.34
Inventory Turnover
7.85
Capex per Share
0.02

Balance Sheet

Cash per Share
0,35
Book Value per Share
0,29
Tangible Book Value per Share
0.19
Shareholders Equity per Share
0.29
Interest Debt per Share
0.15
Debt to Equity
0.52
Debt to Assets
0.2
Net Debt to EBITDA
1.67
Current Ratio
1.49
Tangible Asset Value
0,09 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
200030000
Working Capital
0,08 Bil.
Intangibles to Total Assets
0.14
Average Receivables
0,02 Bil.
Average Payables
0,01 Bil.
Average Inventory
13606000
Debt to Market Cap
0.5

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

23andMe Holding Co. Dividends
Year Dividends Growth

23andMe Holding Co. Profile

About 23andMe Holding Co.

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

CEO
Ms. Anne Wojcicki
Employee
560
Address
349 Oyster Point Boulevard
South San Francisco, 94080

23andMe Holding Co. Executives & BODs

23andMe Holding Co. Executives & BODs
# Name Age
1 Mr. Guy Chayoun
Vice President, Interim General Counsel & Corporate Secretary
70
2 Mr. Jonathan Ward
Chief Marketing Officer
70
3 Ms. Anne Wojcicki
Co-Founder, Chief Executive Officer, President & Chair of the Board
70
4 Ms. Katie Watson
Vice President of Communications
70
5 Mr. Eli Fry
Vice President of Operations
70
6 Mr. Joseph Selsavage
Chief Financial & Accounting Officer
70

23andMe Holding Co. Competitors